Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics Announces Planned CEO Succession
05:02pm, Thursday, 28'th May 2026
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08:30am, Tuesday, 26'th May 2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
11:21am, Thursday, 14'th May 2026
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
07:50am, Thursday, 14'th May 2026
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics Q1 Earnings Call Highlights
08:15pm, Wednesday, 13'th May 2026
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April finan
Allogene Therapeutics ends China cell therapy deal with Overland
05:05pm, Wednesday, 13'th May 2026
Allogene Therapeutics said on Wednesday it has ended a key partnership for developing cell therapies in parts of Asia and reworked its equity stake in partner Overland Therapeutics.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
04:02pm, Wednesday, 13'th May 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
08:30am, Wednesday, 06'th May 2026
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
08:30am, Tuesday, 21'st Apr 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
08:30am, Monday, 20'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 13.1% After Analyst Upgrade
01:48am, Friday, 17'th Apr 2026
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day trading on Thursday after JPMorgan Chase and Co. upgraded the stock from an underweight rating to a neu
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
04:01pm, Thursday, 16'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,50
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
09:50pm, Tuesday, 14'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its co
